|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
Entero Therapeutics, Inc. (Name of Issuer) |
Common stock, par value $0.0001 per share (Title of Class of Securities) |
33749P408 (CUSIP Number) |
Arif Nasir Ali 1841 Chondra Dr, Marietta, GA, 30062 404 480 8000 Charlie Jarrett, Attorney 2302 Parklake Drive NE, Suite 420 Atlanta, GA, 30345 404 490 4060 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/06/2025 (Date of Event Which Requires Filing of This Statement) |
SCHEDULE 13D
|
| CUSIP No. | 33749P408 |
| 1 |
Name of reporting person
Ali Arif Nasir | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
230,900.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. | 33749P408 |
| 1 |
Name of reporting person
Arif Ali IRA Roth | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
147,900.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
3.1 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. | 33749P408 |
| 1 |
Name of reporting person
ANARP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
WYOMING
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
62,800.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
1.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. | 33749P408 |
| 1 |
Name of reporting person
ANANRA LLC TRUST | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
GEORGIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
20,200.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.4 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
Entero Therapeutics, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
777 YAMATO ROAD, 777 YAMATO ROAD, BOCA RATON,
FLORIDA
, 33431. | |
Item 1 Comment:
This Amendment No. 1 amends the statement on Schedule 13D originally filed with the U.S. Securities and Exchange Commission on June 9, 2025 (together with all amendments through the date hereof, this "Schedule 13D"). This Schedule 13D relates to shares of common stock, $0.0001 par value per share (the "Common Stock"), of Entero Therapeutics, Inc., (the "Issuer"), whose principal executive offices are located at 777 Yamato Road, Suite 502, Boca Raton, Florida. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | As of June 6, 2025, the Reporting Persons beneficially owned in the aggregate 230,900 shares of Common Stock, constituting approximately 4.85% of the outstanding Common Stock. The following sets forth certain information with respect to shares of Common Stock directly beneficially owned by the Reporting Persons listed below:
ANARP LLC beneficially owns 62800 shares of common stock representing 1.32% of the outstanding common stock. Arif Ali IRA Roth beneficially owns 147900 shares of common stock representing 3.10% of the outstanding common stock. ANANRA LLC TRUST beneficially owns 20200 shares of common stock representing 0.42% of the outstanding common stock.
Arif Ali is the owner of Arif Ali IRA Roth, Manager of ANARP LLC and a Trustee of ANANRA LLC TRUST and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) of the Common Stock that Arif Ali IRA Roth, ANARP LLC and ANANRA LLC TRUST own. Mr. Ali has the sole power to vote or direct the vote or to dispose of 230,900 shares of Common Stock. None of Arif Ali IRA Roth, ANARP LLC or ANANRA LLC TRUST have power to vote or direct the vote or to dispose any shares of Common Stock. | |
| (b) | Beneficial ownership of the Common Stock shown on the cover pages of and set forth elsewhere in this statement for each of the Reporting Persons assumes that they have not formed a group for purposes of Section 13(d)(3) under the Exchange Act, and Rule 13d-5(b)(1) promulgated thereunder. If the several Reporting Persons were deemed to have formed a group for purposes of Section 13(d)(3) and Rule 13d-5(b)(1), the group would be deemed to own beneficially (and may be deemed to have shared voting and dispositive power over) in the aggregate 230,900 shares of Common Stock, constituting approximately 4.85% of the outstanding shares of Common Stock.
The percentage of shares of Common Stock reported as being beneficially owned is based on 4,765,729 shares of Common Stock outstanding as reported in the 10Q report for quarter ending March 31, 2025 filed on May 15, 2025. | |
| (c) | The following sets forth certain information with respect to shares of Common Stock transacted by the Reporting Persons listed below since the most recent filing of Schedule 13D. Each of the below transactions was effected through the open market:
ANARP LLC sold 20,000 shares of common stock on 6/6/2025 at $0.50 per share. | |
| (d) | Not applicable. | |
| (e) | The Reporting Persons ceased to be beneficial owners of 5% or more of shares of the Common Stock on June 6, 2025. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Not applicable. | ||
| Item 7. | Material to be Filed as Exhibits. | |
Not applicable. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|